Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
After finishing at $3.69 in the prior trading day, Esperion Therapeutics Inc (NASDAQ: ESPR) closed at $3.95, up 7.05%. In other words, the price has increased by $7.05 from its previous closing price. On the day, 11.05 million shares were traded. ESPR stock price reached its highest trading level at $4.0189 during the session, while it also had its lowest trading level at $3.64.
Ratios:
Our goal is to gain a better understanding of ESPR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.76 and its Current Ratio is at 1.15.
Upgrades & Downgrades
In the most recent recommendation for this company, Piper Sandler on November 25, 2025, initiated with a Overweight rating and assigned the stock a target price of $9.
On December 18, 2024, Goldman started tracking the stock assigning a Neutral rating and target price of $4.
On December 17, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $8.Cantor Fitzgerald initiated its Overweight rating on December 17, 2024, with a $8 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 17 ’25 when Looker Benjamin bought 1,248 shares for $2.62 per share.
Looker Benjamin sold 6,267 shares of ESPR for $17,573 on Sep 17 ’25. The General Counsel now owns 393,670 shares after completing the transaction at $2.80 per share. On Sep 17 ’25, another insider, Koenig Sheldon L., who serves as the President and CEO of the company, sold 28,427 shares for $2.79 each. As a result, the insider received 79,254 and left with 1,518,831 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ESPR now has a Market Capitalization of 936423488 and an Enterprise Value of 1444961536. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.11. Its current Enterprise Value per Revenue stands at 4.756 whereas that against EBITDA is -49.36.
Stock Price History:
The Beta on a monthly basis for ESPR is 0.99, which has changed by 0.41071427 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, ESPR has reached a high of $3.94, while it has fallen to a 52-week low of $0.69. The 50-Day Moving Average of the stock is 39.16%, while the 200-Day Moving Average is calculated to be 119.63%.
Shares Statistics:
The stock has traded on average 7.20M shares per day over the past 3-months and 7725330 shares per day over the last 10 days, according to various share statistics. A total of 239.06M shares are outstanding, with a floating share count of 234.63M. Insiders hold about 1.86% of the company’s shares, while institutions hold 53.00% stake in the company. Shares short for ESPR as of 1763078400 were 24958080 with a Short Ratio of 3.46, compared to 1760486400 on 24416434. Therefore, it implies a Short% of Shares Outstanding of 24958080 and a Short% of Float of 10.569999.
Earnings Estimates
The dynamic stock of Esperion Therapeutics Inc (ESPR) is currently attracting attention from 7.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.01, with high estimates of $0.07 and low estimates of -$0.06.
Analysts are recommending an EPS of between $0.23 and -$0.42 for the fiscal current year, implying an average EPS of -$0.07. EPS for the following year is $0.03, with 7.0 analysts recommending between $0.4 and -$0.32.
Revenue Estimates
8 analysts predict $164.7M in revenue for. The current quarter. It ranges from a high estimate of $211.4M to a low estimate of $97.33M. As of. The current estimate, Esperion Therapeutics Inc’s year-ago sales were $69.11MFor the next quarter, 8 analysts are estimating revenue of $109.49M. There is a high estimate of $155.84M for the next quarter, whereas the lowest estimate is $88.1M.
A total of 8 analysts have provided revenue estimates for ESPR’s current fiscal year. The highest revenue estimate was $446.1M, while the lowest revenue estimate was $283.93M, resulting in an average revenue estimate of $393.11M. In the same quarter a year ago, actual revenue was $332.31MBased on 8 analysts’ estimates, the company’s revenue will be $379.59M in the next fiscal year. The high estimate is $433.01M and the low estimate is $339.03M.
